Enzene Biosciences Ltd

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world. It has been growing at about 25.5% CAGR over the last 5 years and crossed the $1.9 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 69% of its revenue coming from global business.

Currently ranked 9th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology and Oncology in India. It is also known for its range of products in other hospital-based therapeutic segments in the EU and US.

Intas operates 15 formulation, R&D and distribution facilities, of which 10 are in India, and the rest in the UK and Mexico. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars and NDDS products.

Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “biosimilars for billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies.

The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP certified manufacturing facility complemented with a GLP compliant QC lab.

Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces of our excellence.

Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India. It has strong presence in Branded Generic business in India & Emerging markets; and Generic business in USA.

In India, company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology and Pain management. It's brands hold leadership positions in sub-therapeutic areas they are present in.

In Emerging Markets, company has presences in Africa, South East Asia, West Asia, and CIS on broader therapeutic segments such as anti-malarial, gastro, antibiotics, cardiology, dermatology, pain management, etc.

As on 31 March 2021, Ajanta has 36 ANDA approvals which are commercialised. And it is awaiting US FDA approval for 15 ANDAs. Company plans to file 10-12 ANDAs during the current financial year.

Company has state-of-the-art research facilities for formulation and API development located at Mumbai, India. R&D capabilities are evident from number of 1st to market products launched by the company providing patients most needed compliance and convenience. A dedicated and focused team of over 650+ scientists work for R&D, which is growing continuously.

Ajanta has 6 formulations manufacturing facilities located in India and 1 in Mauritius. Besides that, it also has an API manufacturing facility located at Waluj, India. Ajanta’s flagship formulation facilities at Paithan (Maharashtra, India) and Dahej (Gujarat, India) have been approved by US FDA.

Ajanta continuously invests in enhancing the existing manufacturing facilities to meet current cGMP requirements and also construct new facilities to meet company’s growth requirements.

Please visit http://ajantapharma.com/ for more information.

BIONEEDS INDIA PRIVATE LIMITED is a Bangalore based Contract Research Organization providing Integrated Discovery, Development and Regulatory Services to Pharmaceutical,
Biopharmaceutical, Agrochemical, Industrial chemical, Herbal/Nutraceutical and Medical device companies.

Accreditation/Certifications
• National GLP Compliance Monitoring Authority (NGCMA), Dept. of Science and Technology, Government of India
• Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment, Forests and Climate Change, GOI.
• State Drug Controller as a Government approved Drug Testing Laboratory for carrying out tests on Drugs / Cosmetics and
• Raw Materials used in their manufacture on behalf of licensees for manufacture for sale of drugs / cosmetics
• Review Committee on Genetic Manipulation (RCGM), department of biotechnology, GOI to conduct experiments on animals for DNA or Genetically modied resources
• Bioneeds is AAALAC certified for laboratory animal care
• Bioneeds’ in-house R & D unit is recognised by Department of Scientic and Industrial Research (DSIR)
• ISO 17025 certified for Biological evaluation of Medical Devices
• Bioneeds has best-in-class infrastructure equipped with state-of-the-art facilities with 2,50,000 sqft built-up area.
• Vivarium with 85 exclusive animal rooms built as per international standards
• Cutting edge Drug Discovery and Development Labs to support Medicinal chemistry, Biology, In vivo Pharmacology,
• Toxicology, Custom synthesis, Process R&D, cGMP manufacturing, Formulation and Analytical development services

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented Pharma Company with presence in 55 countries. Indoco, a USD 166 million company, employs over 6000 people including over 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by various regulatory authorities such as USFDA, UK-MHRA, DRU Botswana, PMDA-Japan, TGA-Australia, FMHACA-Ethiopia, DPML- Ivory Coast, SAHPRA- South Africa, NDA-Uganda, etc.

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals,  Cardiovascular, Anti-Diabetics, Pain Management  etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital,  Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM, Methycal, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

Indoco has carved a place for itself in the international arena and is exporting a number of generic products in the Regulated and Emerging Markets. Indoco’s branded formulations are promoted in Emerging Markets of South East Asia, Africa, Latin America and CIS countries. The Company participates in various tenders floated by authorities from different countries. Indoco has tie-ups with large generic companies across the globe and works in close coordination with its customers for leveraging core competencies.

Indoco Analytical Solutions division has been carved to serve customers for their analytical research needs. AnaCipher CRO, Hyderabad, is a USFDA inspected facility providing clinical trial solutions, BA/BE/Phase I/Phase studies.

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949.

When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti.

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.

Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

- One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally
- 15 APIs & 11 Formulations manufacturing facility across the globe
Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis
- Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy
- 4 formulations rank amongst the top 300 brands of IPM as per IQVIA